ProQR Teams with Ginkgo’s Nebula Lab, Forms AI Board; AI Candidate Clinic 2026
ProQR partnered with Ginkgo Bioworks to leverage Nebula’s 50+ instrument autonomous lab for high-throughput data generation to accelerate its AI-enabled Axiomer™ drug discovery. The company formed an AI Advisory Board of industry and academic leaders and expects its first AI-designed candidate in clinic in 2026.
1. Partnership with Ginkgo Bioworks
ProQR’s collaboration with Ginkgo Bioworks grants access to Ginkgo’s Nebula autonomous lab equipped with over 50 instruments, enabling high-throughput generation of experimental data. This integration is designed to remove bottlenecks in AI-enabled drug discovery, improving model training speed and scale, and accelerating candidate identification.
2. Formation of AI Advisory Board
ProQR has established an AI Advisory Board comprising distinguished leaders from industry and academia, including experts from NVIDIA, Hugging Face and Leiden University. The board will guide best practices and emerging AI approaches to optimize Axiomer™ editing oligonucleotides and enhance the company’s discovery strategy.
3. AI-Enabled Pipeline Milestones
The first drug candidate generated through ProQR’s AI-enabled Axiomer™ platform is slated to enter clinical trials in mid-2026, with initial data expected by year-end 2026. This milestone marks a key validation of the company’s AI-driven discovery model and sets the stage for accelerated pipeline expansion.